Document Detail

Metabolite Profiling of Bendamustine in Urine of Cancer Patients after Administration of [14C]Bendamustine.
MedLine Citation:
PMID:  22492615     Owner:  NLM     Status:  Publisher    
Bendamustine is an alkylating agent consisting of a mechlorethamine derivative, a benzimidazole group, and a butyric acid substituent. A human mass balance study showed that bendamustine is extensively metabolized and subsequently excreted in urine. Limited information, however, is available on the metabolite profile of bendamustine in human urine. The objective of this study was to elucidate the metabolic pathways of bendamustine in humans by identification of its metabolites excreted in urine. Human urine samples were collected up to 168 h after an intravenous infusion of 120 mg/m(2), 80-95 μCi [(14)C]bendamustine. Metabolites of [(14)C]bendamustine were identified using liquid chromatography (high resolution) tandem mass spectrometry with off-line radioactivity detection. Bendamustine and a total of 25 bendamustine-related compounds were detected. Observed metabolic conversions at the benzimidazole and butyric acid moiety were N-demethylation and γ-hydroxylation. Additionally, various other combinations of these conversions with modifications at the mechlorethamine moiety were observed, including hydrolysis (the primary metabolic pathway), cysteine conjugation and subsequent biotransformation to mercapturic acid and thiol derivatives, N-dealkylation, oxidation, and conjugation with phosphate, creatinine, and uric acid. Bendamustine-derived products containing phosphate, creatinine, and uric acid conjugates were also detected in control urine incubated with bendamustine. Metabolites that were excreted up to 168 h after the infusion included products of dihydrolysis and cysteine conjugation of bendamustine and γ-hydroxybendamustine. The range of metabolic reactions is generally consistent with those reported for rat urine and bile, suggesting that the overall processes involved in metabolic elimination are qualitatively the same in rats and humans.
Anne Charlotte Dubbelman; Robert S Jansen; Hilde Rosing; Mona Darwish; Edward Hellriegel; Philmore Robertson; Jan H M Schellens; Jos H Beijnen
Related Documents :
6170345 - The hexa- and pentapeptide extension of proalbumin. i. chemical synthesis of serum albu...
597595 - The origin of the protein synthesis mechanism.
9304095 - Vestiges of early molecular processes leading to the genetic code.
9230485 - Total synthesis of zervamicin iib and its deuterium-labelled analogues.
8136015 - Thermal inactivation of butyrylcholinesterase and acetylcholinesterase.
1153355 - The study of the bioavailability of coated acetylsalicylic acid in suppositories after ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-4
Journal Detail:
Title:  Drug metabolism and disposition: the biological fate of chemicals     Volume:  -     ISSN:  1521-009X     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9421550     Medline TA:  Drug Metab Dispos     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
1 Netherlands Cancer Institute / Slotervaart Hospital;
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Selective Reduction of Biomass by Hydriodic Acid and Its In?Situ Regeneration from Iodine by Metal/H...
Next Document:  Chain Elongation and Cyclization in Type III PKS DpgA.